Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Generated: May 25, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022185

« Back to Dashboard

NDA 022185 describes TACLONEX, which is a drug marketed by Leo Pharma As and is included in two NDAs. It is available from three suppliers. There are two patents protecting this drug and one Paragraph IV challenge. Additional details are available on the TACLONEX profile page.

The generic ingredient in TACLONEX is betamethasone dipropionate; calcipotriene hydrate. There are sixty-six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the betamethasone dipropionate; calcipotriene hydrate profile page.

Summary for 022185

Tradename:	TACLONEX
Applicant:	Leo Pharma As
Ingredient:	betamethasone dipropionate; calcipotriene hydrate
Patents:	2
Formulation / Manufacturing:	see details

Pharmacology for NDA: 022185

Ingredient-type	Vitamin D
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

Suppliers and Packaging for NDA: 022185

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
TACLONEX	betamethasone dipropionate; calcipotriene hydrate	SUSPENSION;TOPICAL	022185	NDA	LEO Pharma Inc.	50222-501	N	50222-501-06
TACLONEX	betamethasone dipropionate; calcipotriene hydrate	SUSPENSION;TOPICAL	022185	NDA	LEO Pharma Inc.	50222-501	N	50222-501-51

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	SUSPENSION;TOPICAL			Strength	0.064%;0.005%
Approval Date:	May 9, 2008	TE:		RLD:	Yes
Patent:	➤ Try a Free Trial	Patent Expiration:	Jan 27, 2020	Product Flag?	Y	Substance Flag?		Delist Request?
Patented Use:	PLAQUE PSORIASIS
Patent:	➤ Try a Free Trial	Patent Expiration:	Jan 27, 2020	Product Flag?	Y	Substance Flag?		Delist Request?
Patented Use:	PSORIASIS
Patent:	➤ Try a Free Trial	Patent Expiration:	Jan 27, 2020	Product Flag?	Y	Substance Flag?		Delist Request?
Patented Use:	TREATMENT OF MODERATE PLAQUE PSORIASIS

Expired US Patents for NDA 022185

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Leo Pharma As	TACLONEX	betamethasone dipropionate; calcipotriene hydrate	SUSPENSION;TOPICAL	022185-001	May 9, 2008	➤ Try a Free Trial	➤ Try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.